Hemoglobin A1c (HbA1c) remains a cornerstone of diabetes diagnosis and long-term glucose monitoring. This blood test measures the percentage of glycated hemoglobin, providing an estimate of average blood glucose levels over the preceding two to three months. However, clinicians and patients alike frequently overlook a critical confounder that can markedly skew A1c results: iron deficiency. Whether accompanied by anemia or not, iron deficiency can alter A1c readings enough to cause misclassification of diabetes risk, inappropriate treatment intensification, and delayed diagnosis of other medical issues. For healthcare providers and patients striving for precision diabetes care, understanding this interaction is essential.

Iron deficiency is the most common nutritional deficiency worldwide, affecting an estimated 30% of the global population. Among individuals with diabetes, prevalence may be even higher due to gastrointestinal blood loss from medications (e.g., aspirin, anticoagulants), concurrent chronic kidney disease, or restrictive diets. When iron deficiency occurs, it does more than reduce red blood cell count; it changes the lifespan, biochemical properties, and hemoglobin composition of red cells—all of which directly interfere with the A1c assay. Failing to account for these effects compromises the reliability of one of the most frequently ordered tests in metabolic medicine.

Recent evidence suggests that the magnitude of the A1c shift can be clinically meaningful. A systematic review and meta-analysis published in Diabetes Research and Clinical Practice (2020) reported that individuals with iron deficiency anemia had A1c values approximately 0.3–0.5 percentage points higher than those with normal iron stores, after adjusting for glycemic levels. This seemingly modest increase can push a patient with prediabetes into the diagnostic range for diabetes or make a well-controlled diabetic appear to have poor glycemic control. With the global rise in both diabetes and iron deficiency, clinicians must integrate this knowledge into daily practice.

What Is Hemoglobin A1c and How Is It Measured?

Hemoglobin A1c is formed when glucose in the bloodstream non‑enzymatically binds to the N‑terminal valine of the beta‑chain of hemoglobin A. This reaction is irreversible and gradually accumulates over the lifetime of red blood cells, which typically circulate for about 120 days. Therefore, A1c reflects the integrated blood glucose concentration over roughly the preceding 8–12 weeks. The American Diabetes Association (ADA) recommends A1c below 5.7% for normal glucose tolerance, 5.7%–6.4% for prediabetes, and 6.5% or higher for diabetes diagnosis. Treatment targets are usually 7.0% or lower for most nonpregnant adults with diabetes.

Standard A1c assays use high‑performance liquid chromatography (HPLC), immunoassays, or enzymatic methods. These tests are calibrated to measure glycation within a normal red blood cell lifespan and hemoglobin composition. Critically, any condition that alters red blood cell turnover or hemoglobin structure can distort the relationship between A1c and actual glycemia. This is where iron deficiency enters as a frequent confounder, along with other conditions such as hemolytic anemia, recent blood transfusion, or hemoglobinopathies.

How Iron Deficiency Alters A1c Results

The effect of iron deficiency on A1c is multifaceted and sometimes counterintuitive. While the predominant clinical finding is that iron deficiency falsely elevates A1c, several distinct mechanisms contribute, and in rare cases the effect can be reversed. Understanding these mechanisms helps clinicians interpret discrepant results.

Mechanism 1: Prolonged Red Blood Cell Lifespan

Iron deficiency reduces erythropoietin responsiveness and bone marrow output, leading to a population of older red blood cells that survive longer in circulation. Because A1c accumulates linearly over the cell’s life, older cells have more time to become glycated, thereby increasing the measured percentage even when ambient glucose levels are normal. This is the most frequently cited explanation for falsely elevated A1c and is supported by labeled erythrocyte survival studies.

Mechanism 2: Altered Hemoglobin Glycation Kinetics

Iron deficiency changes the intraerythrocytic environment, including increased oxidative stress and altered glucose metabolism. Some studies suggest that iron‑deficient red cells have increased glucose uptake or elevated hexokinase activity, which accelerates non‑enzymatic glycation. This biochemical shift can further inflate A1c independently of cell age, amplifying the effect in proportion to the severity of iron depletion.

Mechanism 3: Redistribution of Hemoglobin Species

In iron deficiency, the relative proportions of hemoglobin A, A2, and F may shift. Since A1c only measures glycation of hemoglobin A, changes in hemoglobin variant percentages can confound assay calibration. Most automated methods are designed for a normal hemoglobin A proportion (≥95%); deviations can lead to underestimation or overestimation depending on the assay method. For example, some HPLC methods may incorporate hemoglobin A2 into the calculation, while others do not, creating variability.

Mechanism 4: Increased Oxidative Stress and Inflammation

Iron deficiency often coexists with chronic inflammation, which itself affects red blood cell turnover and glycation. Elevated inflammatory cytokines can shorten red cell lifespan in some contexts while prolonging it in others. This interplay complicates the interpretation of A1c in populations with high inflammatory burden, such as those with obesity, metabolic syndrome, or autoimmune disease. Additionally, oxidative stress can directly modify hemoglobin and interfere with certain assay chemistries.

These mechanisms highlight why simply assuming that iron deficiency always raises A1c is an oversimplification. However, the predominant clinical finding—consistent across large epidemiological studies—is that iron deficiency is associated with higher A1c values at any given level of glycemia. The effect is most pronounced in moderate to severe iron deficiency anemia, but even subclinical iron depletion (without anemia) can produce a significant bias.

Implications for Diabetes Diagnosis and Management

The consequences of unaccounted iron deficiency extend across the entire diabetes care spectrum. Misleading A1c results can lead to:

  • Overdiagnosis of diabetes: Healthy individuals with iron deficiency may be misclassified as having prediabetes or diabetes, leading to unnecessary stress, medications, and healthcare costs. This is particularly problematic in screening programs where A1c is used as the sole diagnostic test.
  • Unnecessary treatment intensification: A diabetic patient with controlled glucose but iron deficiency may appear to have an elevated A1c, prompting clinicians to add or increase hypoglycemic agents. This can cause dangerous hypoglycemia if the patient’s true glucose level is actually on target or below target.
  • Delayed treatment for anemia: Conversely, if a diabetic patient has both high A1c and iron deficiency, the provider may assume glucose is poorly controlled when part of the elevation is due to anemia. The underlying iron deficiency may go untreated, worsening fatigue, cardiovascular risk, and quality of life.
  • Misguided research conclusions: In clinical trials that rely solely on A1c as an endpoint, unrecognized iron deficiency can introduce systematic bias, obscuring true treatment effects on glycemic control and potentially leading to incorrect dosing recommendations.

A landmark analysis from the National Health and Nutrition Examination Survey (NHANES) showed that among adults without diabetes, those with iron deficiency had a mean A1c 0.2% higher than those with normal iron stores, after adjusting for age, sex, BMI, and fasting glucose. This seemingly small shift can push many individuals above the diagnostic threshold for prediabetes (5.7%), particularly those with borderline values. In one simulation, correcting iron deficiency reduced the prevalence of prediabetes by approximately 10–15% in iron‑deficient populations.

Strategies for Healthcare Providers

Given the prevalence of iron deficiency and its potential to distort A1c, clinical teams must adopt proactive strategies to preserve diagnostic accuracy. Below are evidence‑based recommendations drawn from endocrinology guidelines, hematology consensus statements, and recent systematic reviews.

Screen for Iron Deficiency in At‑Risk Patients

Any patient with unexplained A1c elevation—especially if fasting glucose remains normal or the glucose management indicator (GMI) from continuous glucose monitoring does not match the A1c—should undergo iron studies. The most useful screening tests include:

  • Serum ferritin: Low ferritin (<30 ng/mL) indicates depleted iron stores. However, ferritin is an acute‑phase reactant; in inflammatory states (common in diabetes), a higher threshold (e.g., <100 ng/mL) may be needed to detect functional iron deficiency.
  • Transferrin saturation: Values below 20% suggest iron deficiency, especially when combined with low ferritin.
  • Complete blood count with red cell indices: Microcytic hypochromic anemia (low MCV, low MCH) raises suspicion, but iron deficiency can exist without anemia. Mean corpuscular hemoglobin concentration (MCHC) may also be decreased.

According to a 2023 consensus statement from the International Federation of Clinical Chemistry and Laboratory Medicine, all patients with diabetes whose hemoglobin is <13 g/dL (men) or <12 g/dL (women) should have their iron status evaluated before interpreting A1c. For patients with borderline ferritin, a trial of iron therapy with repeat A1c after 3 months can be diagnostic.

Interpret Discordant A1c and Glucose Levels with a Structured Approach

When A1c and glucose measures are discrepant (e.g., A1c ≥6.5% but fasting glucose <126 mg/dL), create a differential diagnosis that includes:

  • Iron deficiency (most common in women, elderly, vegetarians, and after bariatric surgery)
  • Hemoglobinopathies (sickle cell trait, thalassemia)
  • Chronic kidney disease (altered red cell survival)
  • Recent blood transfusion or erythropoietin therapy
  • Hemolytic anemias (shortened red cell lifespan)
  • Laboratory assay interference (e.g., carbamylated hemoglobin in uremia)

A thorough history and targeted lab work (iron panel, hemoglobin electrophoresis, renal function) can clarify the cause. Remember that iron deficiency is the most treatable and common cause in many populations.

Use Alternative Glucose Monitoring Methods

When iron deficiency is present or suspected, rely on complementary metrics that are not affected by red blood cell lifespan or hemoglobin structure:

  • Fasting plasma glucose (FPG) and oral glucose tolerance test (OGTT) remain valid for diagnosis, though they reflect single time points and may miss postprandial hyperglycemia.
  • Continuous glucose monitoring (CGM) provides multiple days of data and can calculate the glucose management indicator (GMI), which correlates with A1c but is unaffected by red cell turnover. CGM is increasingly recommended for diabetes management in individuals with conditions that interfere with A1c.
  • Fructosamine or glycated albumin reflect shorter‑term glycemia (2–3 weeks) and are not influenced by iron status. However, they are less standardized than A1c for diagnosis and may be affected by low albumin levels.
  • Point‑of‑care A1c devices may use different assay principles; their performance in iron deficiency varies widely and cannot be assumed to be more accurate. Always verify with a laboratory method if discrepancy exists.

Correct Iron Deficiency Before Making Diabetes Decisions

If iron deficiency is confirmed, treatment with oral iron (ferrous sulfate, ferrous gluconate, or ferric carboxymaltose) should be initiated. In patients with intolerance or malabsorption, intravenous iron (e.g., ferric carboxymaltose, iron isomaltoside) is effective. Following iron repletion, A1c levels typically decrease by 0.2–0.5% as red blood cell turnover normalizes and younger cells become the predominant population. A repeat A1c measurement 3 months after iron therapy provides a more accurate reflection of true glycemic control. Do not escalate diabetes therapy solely based on a high A1c in the presence of uncorrected iron deficiency unless concurrent glucose monitoring (FPG, CGM, or fructosamine) confirms hyperglycemia.

Patient Education and Shared Decision-Making

Patients should understand that anemia can affect their blood sugar test results. For example, a woman of childbearing age with heavy menstrual bleeding and diabetes may see fluctuating A1c levels that do not reflect her diet or medication adherence. Educating patients to report symptoms of iron deficiency (fatigue, pallor, shortness of breath, pica, restless legs) empowers them to be partners in care. In shared decision-making, explain that A1c is not always a perfect measure and that treating underlying iron deficiency can improve the accuracy of diabetes monitoring.

Special Populations and Considerations

Pregnancy

Pregnancy is associated with physiologic dilutional anemia and high rates of iron deficiency. A1c is not recommended for gestational diabetes diagnosis because of these changes; the preferred approach is the 75‑g OGTT at 24–28 weeks. For women with pre‑existing diabetes who become pregnant, iron deficiency should be corrected to avoid overestimation of glycemic control, which could lead to insufficient insulin dosing and worse perinatal outcomes. In lactating women, ongoing iron supplementation may help maintain accurate A1c monitoring.

Chronic Kidney Disease

Patients with chronic kidney disease (CKD) often have both anemia (due to erythropoietin deficiency and iron deficiency) and altered A1c reliability. In CKD stages 4–5, A1c may underestimate true glycemia because of shortened red blood cell survival. The co‑occurrence of iron deficiency further complicates interpretation, as the net effect depends on the balance of factors. In such patients, CGM or glycated albumin is preferred for glycemic assessment. The ADA’s Standards of Care now recommend using CGM or fructosamine in patients with CKD and conditions that interfere with A1c.

Older Adults

Elderly individuals frequently have nutritional deficiencies, including iron deficiency, and have a higher prevalence of diabetes. A1c targets in older adults are often individualized (e.g., <8.0% in frail patients with limited life expectancy). If iron deficiency is present and corrected, the A1c may drop, potentially pushing an older patient below their glycemic target and necessitating reduction of hypoglycemic medications. Careful monitoring is essential to prevent hypoglycemia in this vulnerable population.

Children and Adolescents

Iron deficiency is common in children, especially during rapid growth or in those with restrictive diets (e.g., vegan, vegetarian). Children with diabetes may have A1c values that are artificially elevated due to underlying iron deficiency. The effect has been documented in pediatric populations, with iron depletion correlating with higher A1c independent of glycemic control. Pediatric endocrinologists should maintain a low threshold for checking iron studies in children with unexplained A1c elevation or growth concerns.

Bariatric Surgery Patients

Bariatric surgery, particularly Roux‑en‑Y gastric bypass, leads to high rates of iron deficiency due to reduced intestinal absorption and altered dietary intake. Up to 50% of patients develop iron deficiency within 5 years of surgery. Since many bariatric surgery patients also have diabetes or prediabetes, monitoring A1c in this group is particularly problematic. Post‑surgery, if A1c remains elevated despite apparent glucose improvement, iron deficiency should be at the top of the differential. Routine iron supplementation and periodic monitoring of ferritin and transferrin saturation are essential.

Research and Evidence Gaps

While the impact of iron deficiency on A1c is well established, several questions remain for future investigation. The precise magnitude of the effect varies among studies, likely due to differences in the severity of anemia, the methodology of A1c measurement, and the population demography (age, ethnicity, prevalence of hemoglobinopathies). Some authors have proposed that correcting iron deficiency could improve diabetes diagnosis accuracy in low‑resource settings where iron deficiency is rampant and CGM is unavailable. Additionally, the effect might be modified by chronic inflammation or thalassemia trait—common in certain ethnic groups—which itself alters A1c.

Future research should focus on:

  • Developing and validating algorithms that incorporate iron status (e.g., ferritin, transferrin saturation) into personalized A1c interpretation.
  • Examining the effect of iron deficiency on newer diagnostic markers like glycated albumin and CGM‑derived metrics across diverse populations.
  • Evaluating the cost‑effectiveness of routine iron screening in diabetes care, particularly in groups at high risk for deficiency.
  • Determining whether oral versus intravenous iron therapy leads to differential rates of A1c normalization.

Until such evidence is available, a high index of suspicion and pragmatic use of alternative monitoring tools remain the best strategies for clinicians.

External Resources for Further Reading

Clinicians and patients seeking additional information can consult the following authoritative sources:

Key Takeaways for Clinical Practice

  • Iron deficiency anemia commonly elevates A1c by 0.3–0.5% independent of glycemia, increasing the risk of diabetes overdiagnosis and overtreatment.
  • Providers should screen for iron deficiency in patients with discordant A1c and glucose values, especially those with predisposing conditions (heavy menstruation, GI bleeding, CKD, bariatric surgery, vegan diet, older age).
  • Use confirmatory tests—fasting glucose, OGTT, CGM, or glycated albumin—when iron deficiency is present or suspected.
  • Treat iron deficiency before adjusting diabetes therapy based on A1c alone; repeat A1c after 3 months of iron therapy for accurate assessment.
  • Educate patients about the potential effect of anemia on their diabetes test results and encourage reporting of fatigue, pallor, or other symptoms of iron deficiency.
  • In special populations (pregnancy, CKD, elderly, children, post‑bariatric surgery), maintain heightened awareness and use alternative monitoring methods as appropriate.

By integrating this awareness into routine care, healthcare teams can ensure that diabetes diagnoses and management decisions rest on the most accurate foundation possible, improving outcomes for the millions of individuals affected by both iron deficiency and diabetes.